Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repligen Corp RGEN

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial... see more

Recent & Breaking News (NDAQ:RGEN)

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire November 8, 2022

Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

GlobeNewswire November 1, 2022

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

GlobeNewswire November 1, 2022

Repligen to Report Third Quarter 2022 Financial Results

GlobeNewswire October 12, 2022

Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement

GlobeNewswire September 19, 2022

Repligen To Host Investor Day 2022

GlobeNewswire August 24, 2022

Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance

GlobeNewswire August 2, 2022

Repligen to Report Second Quarter 2022 Financial Results

GlobeNewswire July 19, 2022

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

GlobeNewswire May 26, 2022

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire May 25, 2022

Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

GlobeNewswire April 27, 2022

Repligen to Report First Quarter 2022 Financial Results

GlobeNewswire April 13, 2022

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

GlobeNewswire March 18, 2022

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 17, 2022

Repligen Launches AAV Affinity Resins for Gene Therapy Purification

GlobeNewswire February 15, 2022

Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference

GlobeNewswire February 11, 2022

Repligen to Report Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 3, 2022

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 30, 2021

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire November 12, 2021

Repligen Releases Inaugural Sustainability Report

GlobeNewswire November 5, 2021